Company Overview of Bay City Capital LLC
Bay City Capital LLC is a private equity and venture capital firm specializing in restructuring opportunities, and growth investments. It invests in incubation; seed, startup, early, mid, and late stage; PIPES, mezzanine; bridge; and turnaround transactions. The firm prefers to invest in life sciences sector with a focus on biopharmaceuticals, drug discovery and research tools, medical devices, diagnostics, healthcare information technology, nutrition, and agribusiness. It typically invests in North America with a focus on the Great Lakes and Mid-Atlantic region. The firm invests at all stages of development. It also makes select public investments and is a lead or co-lead investor. The firm...
750 Battery Street
San Francisco, CA 94111
Founded in 1997
Key Executives for Bay City Capital LLC
Founder, Managing Director, Investment Partner, Director, and Chairman of the Executive Committee
Managing Director, Operating Partner, and Chief Financial Officer
Managing Director and Investment Partner
Managing Director, Investment Partner, Director, and Member of Executive Committee
Managing Director and Partner
Compensation as of Fiscal Year 2016.
Bay City Capital LLC Key Developments
Bay City Capital LLC Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017
Dec 20 16
Bay City Capital LLC Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: HILTON SAN FRANCISCO UNION SQUARE, 333 O'Farrell Street, San Francisco, CA 94102, United States.
Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd., Bay City Capital and Deerfield Management Announce the Establishment of a New Drug Discovery Company
Oct 31 16
Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases. Bridge Medicines builds upon the work of the independent, non-profit Tri-Institutional Therapeutics Discovery Institute, known as Tri-I TDI. Scientists at the Tri-I TDI, which launched in 2013, are working in the laboratory on approximately 50 early-stage drug discovery projects, spanning therapeutic areas including infectious disease, oncology, neuropsychiatry and rare diseases, with the hope that they might be translated into future treatments for patients. Research projects accepted into the Tri-I TDI will now be able to graduate to Bridge Medicines, where they will be given financial, operational and managerial support to move seamlessly from a validating, proof-of-concept study to an in-human clinical trial. Typically, investigators behind promising early-stage discoveries must search for a biopharmaceutical company to purchase or license their intellectual property, or find a funding opportunity to support additional research. This process can be time consuming and may shift investigators' focus away from science, slowing down and in some cases ending the development path.
Bay City Capital LLC Presents at 9th Annual European Life Sciences CEO Forum & Exhibition, Mar-15-2016 09:30 AM
Jan 4 16
Bay City Capital LLC Presents at 9th Annual European Life Sciences CEO Forum & Exhibition, Mar-15-2016 09:30 AM. Venue: Hilton Zurich Airport Hotel, 27 Belsize Lane, London | NW3 5AS, United Kingdom. Speakers: Lionel Carnot, Managing Director and Investment Partner.
Similar Private Companies By Industry
Recent Private Companies Transactions